

# SCIENTIFIC REPORTS

OPEN

## Role of Berberine in the Treatment of Methicillin-Resistant *Staphylococcus aureus* Infections

Received: 18 December 2015

Accepted: 04 April 2016

Published: 22 April 2016


Ming Chu<sup>1,2</sup>, Ming-bo Zhang<sup>3</sup>, Yan-chen Liu<sup>3</sup>, Jia-rui Kang<sup>4</sup>, Zheng-yun Chu<sup>3</sup>, Kai-lin Yin<sup>1,2</sup>, Ling-yu Ding<sup>1,2</sup>, Ran Ding<sup>3</sup>, Rong-xin Xiao<sup>1</sup>, Yi-nan Yin<sup>1</sup>, Xiao-yan Liu<sup>1</sup> & Yue-dan Wang<sup>1,2</sup>

**Berberine is an isoquinoline alkaloid widely used in the treatment of microbial infections.** Recent studies have shown that berberine can enhance the inhibitory efficacy of antibiotics against clinical multi-drug resistant isolates of methicillin-resistant *Staphylococcus aureus* (MRSA). However, the underlying mechanisms are poorly understood. Here, we demonstrated that sub-minimum inhibitory concentrations (MICs) of berberine exhibited no bactericidal activity against MRSA, but affected MRSA biofilm development in a dose dependent manner within the concentration ranging from 1 to 64 µg/mL. Further study indicated that berberine inhibited MRSA amyloid fibrils formation, which consist of phenol-soluble modulins (PSMs). Molecular dynamics simulation revealed that berberine could bind with the phenyl ring of Phe19 in PSMα2 through hydrophobic interaction. Collectively, **berberine can inhibit MRSA biofilm formation via affecting PSMs' aggregation into amyloid fibrils, and thereby enhance bactericidal activity of antibiotics.** These findings will provide new insights into the multiple pharmacological properties of berberine in the treatment of microbial-generated amyloid involved diseases.


Berberine is an isoquinoline alkaloid presented in various plants<sup>1</sup>, such as *Rhizoma coptidis*<sup>2</sup>, which has been widely used to treat bacterial diarrhea and gastroenteritis for a long history<sup>3,4</sup>. Recently, berberine has been demonstrated to be a strong synergist for antibiotics<sup>5,6</sup>. Synergistic interactions between berberine and commonly used antimicrobial agents exhibit therapeutic benefits against a broad spectrum of pathogenic microorganisms, including methicillin-resistant *Staphylococcus aureus* (MRSA)<sup>7–10</sup>. Many reports have shown that combined use of berberine improved the bactericidal activity of antibiotics against MRSA, lower the MICs of antibiotics, and notably decreased adhesion and intracellular invasion of MRSA<sup>8–10</sup>.

MRSA is one of the most commonly recognized antibiotic-resistant bacteria, which is associated with high morbidity and mortality. The spread of MRSA is of great concern in the treatment of nosocomial infections, since it has quickly acquired resistance to most antibiotics<sup>11</sup>. Recent studies revealed that the antibiotic resistance capabilities of MRSA are associated with biofilm formation, which causes treatment failure and recurrent infections<sup>12–14</sup>. Biofilm acts as a barrier to antimicrobial agents and protect the colonies from any fluctuations of the environment. Microbial biofilm is a structured community of microbial cells enclosed in a self-produced polymeric matrix and adherent to an inert or living surface<sup>15</sup>. An extracellular amyloid fibril has been discovered in all MRSA biofilm matrix, which are composed of small peptides called phenol-soluble modulins (PSMs). PSMs have recently emerged as a novel toxin family contributing to MRSA biofilm development and the dissemination of biofilm-associated infections<sup>16–18</sup>. Notably, ordered aggregation of PSM peptides into amyloid fibrils can abrogate the biofilm disassembly activity ascribed to monomeric PSM peptides<sup>16</sup>. In this study, we investigated the capacity of berberine to inhibit MRSA biofilm formation, and gained insights into the underlying molecular mechanisms.

<sup>1</sup>Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing, 100191, China. <sup>2</sup>Key Laboratory of Medical Immunology, Ministry of Health, Beijing, 100191, China. <sup>3</sup>Pharmacy Departments, Liao Ning University of Traditional Chinese Medicine, Liao Ning, 116600, China. <sup>4</sup>Department of Pathology, the First Affiliated Hospital of General Hospital of Chinese People's Liberation Army, Beijing, 100048, China. Correspondence and requests for materials should be addressed to M.C. (email: famous@bjmu.edu.cn) or Y.-d.W. (email: wangyuedan@bjmu.edu.cn)



**Figure 1. Bacteriostatic activity of berberine against MRSA-ATCC 33591.** MRSA was inoculated into BHI broth and incubated with various concentrations of berberine. LEV (16  $\mu\text{g/mL}$ ) was used as positive control. Inhibition zones were photographed after 48 h incubation at 37 °C. (a) shows the plain agar plates, (b) describes the images for (a).




**Figure 2. Inhibitory effects of berberine on MRSA biofilm formation.** MRSA was inoculated into BHI broth and incubated with various concentrations of berberine. The biofilms that formed on the dish surface were measured by staining with 0.1% safranin. The bound safranin was released from the stained cells with 30% acetic acid. Data are represented as mean  $\pm$  standard deviation. \*Significance was determined at  $P < 0.05$  when compared with the control.

## Results


**Bactericidal activity of berberine.** The susceptibility testing showed that the MIC value of berberine against the tested MRSA-ATCC 33591 strain was 128  $\mu\text{g/mL}$ . It is noted that berberine had no bactericidal activity within the dose range from 1 to 64  $\mu\text{g/mL}$ , but showed a powerful bacteriostatic effect against MRSA on the plain agar plate at 128 and 256  $\mu\text{g/mL}$  (Fig. 1). The mean diameter of the inhibition zone for 128 and 256  $\mu\text{g/mL}$  berberine was 8 and 12 mm, respectively.

**Inhibitory effect of berberine on MRSA biofilm formation.** Biofilms play an intrinsic role in protecting MRSA from any potential antimicrobial agents. Biofilm formation was studied using safranin staining, and the absorbance was measured at 530 nm. The negative control showed an OD of 1.794, whereas experimental groups treated with berberine at 1, 2, 4, 8, 16, 32, and 64  $\mu\text{g/mL}$  showed ODs of 1.779, 1.734, 1.696, 1.327, 0.793, 0.343, and 0.293 respectively (Fig. 2).

Acridine orange is a strong fluorescent biofilm biomass indicator that can stain all microbial colonies in a biofilm, alive or dead. Therefore, we observed the biofilm using a confocal laser scanning microscope (CLSM). CLSM images showed that in the culture without berberine, MRSA produced numerous microbial colonies covering the entire surface of the coverslips. In the culture with 8  $\mu\text{g/mL}$  berberine, the number of colonies was substantially decreased and presented a discrete distribution. A further decrease in colonies occurred in the culture with 16  $\mu\text{g/mL}$  berberine. When the concentration of berberine was over 32  $\mu\text{g/mL}$ , very few colonies were present on the surface coverage of coverslips (Fig. 3).



**Figure 3. CLSM analysis of MRSA biofilms.** MRSA was incubated with different concentrations of berberine (a) control; (b) 4 µg/mL; (c) 8 µg/mL; (d) 16 µg/mL; (e) 32 µg/mL; (f) 64 µg/mL; scale bar = 50 µm. MRSA biofilms were stained with acridine orange, and observed with CLSM at a magnification of 200×.




**Figure 4. SEM analysis of MRSA biofilms.** SEM images of biofilms formed by MRSA incubated with various concentrations of berberine (a) control; (b) 4 µg/mL; (c) 8 µg/mL; (d) 16 µg/mL; (e) 32 µg/mL; (f) 64 µg/mL; scale bar = 5 µm.


The morphology of MRSA biofilm on the surface of coverslips was observed using SEM. Under a 5,000× magnification, biofilm was shown to be composed of many multilayered MRSA colonies. SEM analysis results were consistent with those of acridine orange staining observations. As the concentration of berberine increased, we observed complete biofilm eradication in a dose dependent manner, and an obvious decrease in the density of MRSA (Fig. 4).

**Effect of berberine on microbial amyloid fibril formation.** Congo red is currently used as a sensitive diagnostic tool to visualize microbial-generated amyloids. When grown in berberine-free medium, the MRSA strain showed a classical red, dry and rough phenotype on Congo red-supplemented agar, indicating normal amyloid fibril formation. In the culture with 8 µg/mL berberine, smooth and pink colonies were observed for MRSA producing very few amyloid fibrils. A further decrease of amyloid fibrils was observed in the MRSA colonies which were cultured with 16 µg/mL berberine. Non-amyloid-fibril-producing colonies were observed for MRSA when the concentration of berberine was over 32 µg/mL (Fig. 5).






**Figure 5. Congo red staining of MRSA amyloid fibril.** MRSA was grown on Congo red medium and incubated with various concentrations of berberine (a) control; (b) 4 µg/mL; (c) 8 µg/mL; (d) 16 µg/mL; (e) 32 µg/mL; (f) 64 µg/mL; scale bar = 100 µm. Amyloid-fibril-producing strains show distinctive red colonies.



**Figure 6. Inhibitory effect of berberine on MRSA amyloid fibril.** TEM micrographs of cells from MRSA biofilms in the culture with berberine (a) control; (b) 32 µg/mL. (c) 24 hours after mixing 100 µg/mL each of the seven PSM peptides ( $\alpha$ 1-4,  $\beta$ 1-2, and  $\delta$ -toxin), fibril structures were readily observed by TEM. (d) Few amyloid fibril was observed when PSM peptides were cultured with 32 µg/mL berberine. Bars indicate 500 nm.

TEM imaging of cells revealed the presence of extracellular amyloid fibrils in MRSA biofilms. MRSA has been shown to produce large, extracellular structures (Fig. 6a). When in the culture with 32 µg/mL of berberine, few amyloid fibrils presented in the MRSA biofilms (Fig. 6b). How does berberine affect amyloid fibril formation? It



**Figure 7. Interaction between berberine and PSMα2.** (a) shows the backbone RMSD of PSMα2 during a 36 ns simulation. (b) The minimum distances between berberines (BBE1 and BBE2) and PSMα2 throughout the simulation. (c) The final structure of the simulation was visualized using the PyMOL Molecular Graphics System. (d) The association and dissociation of berberine with synthetic PSMα2 peptide was analyzed using SPR sensor chip.

is known that PSMs can aggregate into the amyloid fibrils in MRSA and modulate their ability to influence the biofilm formation<sup>16</sup>. Therefore, we wondered if berberine can affect PSMs polymerization. Synthetic PSM peptides were allowed to polymerize overnight (Fig. 6c). It is noted that berberine can prevent PSM peptides from aggregating into amyloid fibrils at the concentration of 32 μg/mL (Fig. 6d).

#### Molecular dynamics simulation on the interaction between berberines and a PSM monomer.

To investigate the interaction between berberine and PSMs, we performed a molecular dynamics (MD) simulation using one monomer of PSMs exemplified by PSMα2, two berberines and 20210 water molecules. During a 36 ns simulation, the root-mean-square deviation (RMSD) of PSMα2 backbone rose up to 1.8 nm at 5 ns, and fluctuated around 1.8 nm for the rest of the simulation time, indicating that the PSMα2 has folded into a stable conformation (Fig. 7a). Meanwhile, the minimum distance ( $D_{\min}$ ) between PSMα2 and berberine was measured throughout the simulation (Fig. 7b). Initially, the  $D_{\min}$ s for both of the two berberines were above 1.0 nm, implying that the two berberines were in a state of random diffusion. Then, the  $D_{\min}$  for one berberine (BBE1) drops to 0.25 nm at 5 ns, and the other berberine (BBE2) drops to 0.25 nm at 15 ns. Of note, the  $D_{\min}$  for both berberines kept vibrating around the value until the end of simulation, which indicated that both of the two berberines can bind to PSMα2 and formed a stable complex.

To gain insights into the detailed binding mode between the two berberines and PSMα2, we visualized the final structure of the simulation using the PyMOL Molecular Graphics System. As shown in Fig. 7c, the PSMα2 folded from an extended conformation into a U-shaped structure, with a  $\beta$ -turn in the middle of the peptide, involving residues of Lys9, Val10, Iso11 and Lys12. These four residues adjacent to the  $\beta$ -turn formed a short anti-parallel  $\beta$ -strand. It is noted that both of the two berberines can stack onto the phenyl ring of Phe19 in the PSMα2. In addition, a weak hydrogen bond formed between one of the berberines and the NH group from the backbone of Gly6 in the PSMα2. The binding activity of berberine to PSMα2 was further confirmed using a Surface Plasmon Resonance (SPR) biosensor chip (Fig. 7d). Collectively, berberine might prevent PSMs aggregation *via* disruption of the intermolecular attractions among PSM monomers.

#### Discussion

Berberine is a natural isoquinoline alkaloid drawing increased attention for its multiple therapeutic effects on cancer, diabetes, hyperlipidemia, cardiovascular diseases, and central nervous system (CNS) disorders<sup>19–23</sup>. In traditional medicine, berberine has been widely used to treat bacterial diarrhea and gastroenteritis for a long history. Recently, berberine was demonstrated as a strong synergist for many commonly used antibiotics against clinical

multi-drug resistant isolates of MRSA<sup>8–10</sup>. It is noted that sub-MICs of berberine exhibited significant synergistic effects on four conventional antimicrobial agents, including ampicillin (AMP), azithromycin (AZM), cefazolin (CFZ), and LEV<sup>9</sup>. However, the underlying mechanisms are poorly understood. Our study revealed that the MICs of berberine against MRSA-ATCC 33591 strain was 128 µg/mL with no inhibitory effect within the concentration ranging from 1 to 64 µg/mL. Thus, there might be other possible mechanisms in the synergistic action of berberine besides bactericidal activities.

As known, the antibiotic resistance capabilities of MRSA are associated with biofilm formation. Recent studies have shown that berberine possesses anti-biofilm activity against a broad spectrum of pathogenic microorganisms, such as *S. epidermidis*, *C. albicans*, *Salmonella Typhimurium*, and *S. aureus*<sup>24–28</sup>. Thus, we further investigated the anti-biofilm activity of berberine against MRSA. Biofilm assay revealed that berberine can inhibit the MRSA biofilm formation significantly at the concentrations greater than 8 µg/mL. As the concentration of berberine increased, the number of microbial colonies in the biofilm decreased in a dose dependent manner. It is likely that sub-MICs of berberine possessed promising anti-MRSA activity *via* inhibition of biofilm formation.

The biofilm forming ability of MRSA was reported to be mediated by PSMs, which can be found in biofilms as fibrils with Congo red binding capacities similar to known amyloid proteins, such as amyloid-β peptide (Aβ) in Alzheimer's disease. Soluble PSMs have a helical structure in solution, but transition to adopt a β-rich structure after aggregation<sup>16</sup>. Congo red staining for amyloidosis indicated that berberine affected PSMs' aggregation into amyloid fibrils at the concentrations greater than 8 µg/mL. When in the culture with 32 µg/mL of berberine, few amyloid fibrils presented in the MRSA biofilms. This is presumably mediated by berberine *via* disruption of the intermolecular attractions among PSM monomers. Thus, we gained our insights into the interaction between berberine and PSMα2, which shares a conserved phenylalanine residue with other PSM monomers involved in the amyloid fibrils formation<sup>16</sup>. MD simulation showed that berberines can stack on the phenyl ring of Phe19 in PSMα2 through hydrophobic interaction. Since the π-π stacking between phenylalanine residues from two adjacent β strands is crucial for the aggregation of Aβ-like protein<sup>29,30</sup>, we believed that berberine can prevent PSMs aggregation through destabilizing the π-π stacking of phenylalanine residues.

It is noted that PSMs can modulate biofilm disassembly using amyloids aggregation as a control point for their activity<sup>16</sup>. Soluble PSMs disperse biofilms while polymerized PSM peptides enhanced biofilm formation<sup>17,18</sup>. This work presents evidence that berberine can inhibit MRSA biofilm formation by affecting self-assembling of PSMs into amyloid fibrils, and thus enhancing bactericidal activity of antibiotics. The production of microbial amyloids may be a shared feature of biofilm matrices from many different microbial communities, such as as curli in *Escherichia coli*, TasA in *Bacillus subtilis*, and the Fap fimbriae in *Pseudomonas aeruginosa*<sup>31–33</sup>. Thus, we believe that our research will lead to new approaches in treating persistent biofilm associated infections.

Moreover, berberine has recently gained much attention for its multiple pharmacological properties mediated by targeting molecules, which are involved in a wide range of biological processes, molecular functions and signaling pathways<sup>34–37</sup>. In addition to microbial amyloids, berberine was reported to prevent Aβ aggregation and alter amyloid precursor protein processing<sup>37</sup>, which indicated that berberine may act as a promising agent to combat Alzheimer's disease<sup>38</sup>. Therefore, we propose that further study in the interaction between berberine and microbial-generated amyloids will provide new insights into the potential therapeutic effects of berberine in the treatment of amyloid-involved diseases.

## Methods

**Strains and growth conditions.** Methicillin-resistant *S. aureus* (MRSA-ATCC 33591) strain was used in this study, because it is capable of biofilm formation *in vitro*<sup>39</sup>. MRSA was maintained in tryptic soy broth medium (TSB, Baltimore, MD, USA) and frozen at −80 °C until use. The microorganism was subcultured onto brain-heart infusion agar plates (BHI, Detroit, MI, USA) and incubated at 37 °C for 24 h to generate the bacteria cells for the experiments.

**Antimicrobial agents.** Berberine (Sigma-aldrich, St. Louis, MO, USA) was dissolved in deionized water and filtered through a 0.22 µm Millipore filter (Sartorius Co., NY, USA)<sup>40–42</sup>. Levofloxacin (LEV) was obtained from Yangzhijiang Pharmaceutical Co. (Taizhou, China).

**Susceptibility testing.** The MICs of berberine were determined by a microtitre broth dilution method<sup>7</sup>. Growth inhibition assays were performed in sterile 96-well plates (Corning Co., NY, USA) in a final volume of 200 µL, consisting of 100 µL of microbial cultures ( $5 \times 10^5$  CFU/mL) and 100 µL of serially diluted berberine (2, 4, 8, 16, 32, 64, 128, 256, and 512 µg/mL). Microplates were incubated at 37 °C for 24 h, and the microbial cell growth was assessed by measuring the optical density of cultures at 600 nm wavelength with a Multiskan MK3 microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). All samples were prepared in triplicates. MICs were defined as the lowest berberine concentration that yielded no visible growth after 24 h.

**Agar diffusion test.** Microbial suspension was inoculated into BHI broth and kept for 30 min to allow broth cultures to stabilize. Then, berberine (1, 2, 4, 8, 16, 32, 64, 128, and 256 µg/mL) were added into the agar plate. LEV (16 µg/mL) was used as positive control. Inhibition zones were photographed after 24 h incubation at 37 °C<sup>6</sup>.

**Biofilm assay.** The biofilm assay was based on a method described previously<sup>43</sup>. Berberine was added to the BHI broth containing 1% glucose in 24-well plates (Corning Co., NY, USA). The cultures were then inoculated with a seed culture of MRSA ( $5 \times 10^5$  CFU/mL). After cultivating for 24 h at 37 °C, the supernatant was completely removed, and the wells or wells containing glass coverslips were rinsed with distilled water. The amount of biofilm formed in the wells was measured by staining with 0.1% safranin. The bound safranin was released from the stained cells with 30% acetic acid and the absorbance of the solution was measured at 530 nm. The biofilm formed



on the surface of the glass coverslips was stained with 0.01% acridine orange and observed with a confocal laser scanning microscope (Leica, Heidelberg, Germany).

**Scanning electron microscopy.** The biofilm on glass coverslips was also determined by scanning electron microscopy (SEM)<sup>43</sup>. The biofilm formed on the glass coverslips was rinsed with distilled H<sub>2</sub>O and fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) at 4 °C for 24 h. After gradual dehydration with ethylalcohol (60%, 70%, 80%, 90%, 95%, and 100%), the sample was freeze dried. The specimens were then sputter coated with gold. For observation, a TM3030 SEM (Hitachi, Tokyo, Japan) was used.

**Congo red agar method.** Freeman *et al.* had described a Congo red agar (CRA) method for detecting the production of amyloids by *S. aureus*<sup>44</sup>. The medium was composed of TSB 37 g/L, sucrose 50 g/L, and Congo red (AMERCO, Solon, OH, USA) 0.8 g/L. Congo red stain was prepared as a concentrated aqueous solution and autoclaved (121 °C for 15 min) separately from the other medium constituents, and was then added when the agar had cooled to 55 °C. Plates were inoculated and incubated aerobically for 24 h at 37 °C. Positive result was indicated by red colonies with a dry crystalline consistency. Non-amyloid-fibril-producing strains were usually remained pink, though darkening at the center of the colonies was observed.

**Transmission electron microscopy.** Transmission electron microscopy (TEM) was performed using a JEM-2100 transmission microscope (JOEL, Tokyo, Japan). Samples prepared for TEM imaging were spotted onto formvar-coated copper grids, incubated for 5 mins, washed with sterile distilled H<sub>2</sub>O, and negatively stained with 2% uranyl acetate for 60 seconds<sup>9</sup>.

**PSM polymerization experiments.** PSM peptides ( $\alpha$ 1-4,  $\beta$ 1-2, and  $\delta$ -toxin) were synthesized and prepared as previously described<sup>16</sup>. All assays were performed with equal stoichiometric ratios of 0.1 mg/mL peptide. Synthetic PSM peptides were allowed to polymerize overnight and fibril formation was verified by TEM imaging.

**Molecular dynamics simulation.** The MD simulation was performed using Gromacs 4.5 package<sup>45</sup>. Gromos96 (53A6) force field was used for the PSM $\alpha$ 2<sup>46</sup>. The parameters for the berberine were generated with PRODRG web server<sup>47</sup>. Two berberines were put beside the PSM $\alpha$ 2 with a distance over 1.5 nm. A cubic water box with the length of 9 nm in each side was used to solvate the berberines and PSM $\alpha$ 2. Four Cl<sup>-</sup> ions were added to keep the system neutral in charge. The system was minimized for 1000 steps with the steep decent method, and simulated at 300 K under NPV condition for 100 ps to adapt its density. Then, 36 ns product simulation was conducted under NPT condition. Weak coupling method was used with coupling constants of 0.1 ps and 0.5 ps respectively to maintain the systems at 300 K and 1 Bar. The bonds length involved in the PSM $\alpha$ 2 and berberines were constrained with LINCS, while those in waters were constrained with SETTLE algorithm. Particle Mesh Ewald (PME) method was used to calculate electrostatic interactions beyond the cut off at 10 nm. Van der Waals interactions were cut off at distance of 14 nm and updated every 10 steps. Snapshots of trajectories were saved every 10 ps for analysis.

**Surface Plasmon Resonance biosensor analysis.** Biacore T-100 machine was used for analysis. Synthetic PSM $\alpha$ 2 peptides (fMGIIAGIIKFIKGLIEKFTGK) were immobilized on a sensor chip<sup>48</sup>. Berberine was initially dissolved in 0.1 M sodium acetate buffer of pH 5.0, and further diluted using the running buffer, ranging from 8  $\mu$ g/mL to 32  $\mu$ g/mL. The flow rate was 30  $\mu$ L/min. The kinetic parameters were computed using Biacore T-100 evaluation software.

**Statistical analysis.** The statistical analyses were conducted using Student's t-test with SPSS 13.0 software<sup>49</sup>. The data were expressed as the means  $\pm$  standard deviation. Values of  $p < 0.05$  were considered statistically significant.

## References

- Alolqa, R. N. *et al.* Pharmacokinetics of a multicomponent herbal preparation in healthy Chinese and African volunteers. *Sci. Rep.* **5**, 12961 (2015).
- Yan, D. *et al.* Promotion of quality standard of herbal medicine by constituent removing and adding. *Sci. Rep.* **4**, 3668 (2014).
- Gao, J. *et al.* Synergism and rules of the new combination drug Yiqijiedu formulae (YQJD) on ischemic stroke based on amino acids (AAs) metabolism. *Sci. Rep.* **4**, 5149 (2014).
- Feng, R. *et al.* Transforming berberine into its intestine-absorbable form by the gut microbiota. *Sci. Rep.* **5**, 12155 (2015).
- Musumeci, R. *et al.* *Berberis aetnensis* C. Presl. extracts: antimicrobial properties and interaction with ciprofloxacin. *Int. J. Antimicrob. Agents* **22**(1), 48–53 (2003).
- Han, Y. & Lee, J. H. Berberine synergy with amphotericin B against disseminated candidiasis in mice. *Biol. Pharm. Bull.* **28**(3), 541–544 (2005).
- Wojtyczka, R. D. *et al.* Berberine enhances the antibacterial activity of selected antibiotics against coagulase-negative Staphylococcus strains *in vitro*. *Molecules* **19**(5), 6583–6596 (2014).
- Yu, H. H. *et al.* Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. *J. Med. Food* **8**(4), 454–461 (2005).
- Zuo, G. Y. *et al.* Antibacterial and synergy of berberines with antibacterial agents against clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA). *Molecules* **17**(9), 10322–10330 (2012).
- Liang, R. M. *et al.* Potent *in vitro* synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). *World J. Microbiol. Biotechnol.* **30**(11), 2861–2869 (2014).
- Prosperi, M. *et al.* Molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in the genomic era: a cross-sectional study. *Sci. Rep.* **3**, 1902 (2013).
- Qin, N. *et al.* RNA-Seq-based transcriptome analysis of methicillin-resistant Staphylococcus aureus biofilm inhibition by ursolic acid and resveratrol. *Sci. Rep.* **4**, 5467 (2014).

13. Tan, X. *et al.* Transcriptome analysis of the biofilm formed by methicillin-susceptible *Staphylococcus aureus*. *Sci. Rep.* **5**, 11997 (2015).
14. Santiaqo, C., Lim, K. H., Loh, H. S. & Ting, K. N. Inhibitory effect of *Duabanga grandiflora* on MRSA biofilm formation via prevention of cell-surface attachment and PBP2a production. *Molecules* **20**(3), 4473–4482 (2015).
15. Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: A common cause of persistent infections. *Science* **284**, 1318–1322 (1999).
16. Schwartz, K. *et al.* Functional amyloids composed of phenol soluble modulins stabilize *Staphylococcus aureus* biofilms. *Plos. Pathog.* **8**(6), e1002744 (2012).
17. Tsompanidou, E. *et al.* Requirement of the *agr* locus for colony spreading of *Staphylococcus aureus*. *J. Bacteriol.* **193**, 1267–1272 (2011).
18. Periasamy, S. *et al.* How *Staphylococcus aureus* biofilms develop their characteristic structure. *Proc. Natl. Acad. Sci. USA* **109**(4), 1281–1286 (2012).
19. Tan, W., Li, Y., Chen, M. & Wang, Y. Berberine hydrochloride: Anticancer activity and nano-particulate delivery system. *Int. J. Nanomedicine* **6**, 1773–1777 (2011).
20. Hsu, Y. Y., Tseng, Y. T. & Lo, Y. C. Berberine, a natural antidiabetes drug, attenuates glucose neurotoxicity and promotes Nrf2-related neurite outgrowth. *Toxicol. Appl. Pharmacol.* **272**, 787–796 (2013).
21. Dong, H., Zhao, Y., Zhao, L. & Lu, F. The effects of berberine on blood lipids: A systemic review and meta-analysis of randomized controlled trials. *Planta. Med.* **79**, 437–446 (2013).
22. Derosa, G., Maffioli, P. & Cicero, A. F. Berberine on metabolic and cardiovascular risk factors: An analysis from preclinical evidences to clinical trials. *Expert. Opin. Biol. Ther.* **12**, 1113–1124 (2012).
23. Bhutada, P. *et al.* Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes. *Behav. Brain. Res.* **220**, 30–41 (2011).
24. Wang, X. *et al.* Effect of berberine on *Staphylococcus epidermidis* biofilm formation. *Int. J. Antimicrob. Agents* **34**(1), 60–66 (2009).
25. Wang, X. *et al.* Berberine inhibits *Staphylococcus epidermidis* adhesion and biofilm formation on the surface of titanium alloy. *J. Orthop. Res.* **27**(11), 1487–1492 (2009).
26. Wei, G. X., Xu, X. & Wu, C. D. *In vitro* synergism between berberine and miconazole against planktonic and biofilm *Candida* cultures. *Arch. Oral. Biol.* **56**(6), 565–572 (2011).
27. Liu, Q. *et al.* Synergy among thymol, eugenol, berberine, cinnamaldehyde and streptomycin against planktonic and biofilm-associated food-borne pathogens. *Lett. Appl. Microbiol.* **60**(5), 421–430 (2015).
28. Guo, N. *et al.* The synergy of berberine chloride and totarol against *Staphylococcus aureus* grown in planktonic and biofilm cultures. *J. Med. Microbiol.* **64**(8), 891–900 (2015).
29. Marshall, K. E. *et al.* Hydrophobic, aromatic, and electrostatic interactions play a central role in amyloid fibril formation and stability. *Biochemistry* **50**(12), 2061–2071 (2011).
30. Du, W. J. *et al.* Brazilin inhibits amyloid  $\beta$ -protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity. *Sci. Rep.* **5**, 7992 (2015).
31. Chapman, M. R. *et al.* Role of *Escherichia coli* curli operons in directing amyloid fibril formation. *Science* **295**, 851–855 (2002).
32. Romero, D., Aguilar, C., Losick, R. & Kolter, R. Amyloid fibrils provide structural integrity to *Bacillus subtilis* biofilms. *Proc. Natl. Acad. Sci. USA* **107**, 2230–2234 (2010).
33. Dueholm, M. S. *et al.* Functional amyloid in *Pseudomonas*. *Mol. Microbiol.* **77**, 1009–1020 (2010).
34. Chu, M. *et al.* Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor. *BMC Complement. Altern. Med.* **14**, 89–97 (2014).
35. Balestrini, L. *et al.* Berberine exposure triggers developmental effects on planarian regeneration. *Sci. Rep.* **4**, 4914 (2014).
36. Lee, K. H. *et al.* A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine. *Sci. Rep.* **4**, 6394 (2014).
37. Asai, M. *et al.* Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion. *Biochem. Biophys. Res. Commun.* **352**, 498–502 (2007).
38. Ji, H. F. & Shen, L. Berberine: a potential multipotent natural product to combat Alzheimer's disease. *Molecules* **16**(8), 6732–6740 (2011).
39. Altieri, K. T. *et al.* Effectiveness of two disinfectant solutions and microwave irradiation in disinfecting complete dentures contaminated with methicillin-resistant *Staphylococcus aureus*. *JADA*. **143**, 270–277 (2012).
40. Chu, M. *et al.* Role of Baicalin in anti-influenza virus A as a potent inducer of IFN-gamma. *BioMed Research International*. Article ID 263630 (2015).
41. Chu, M., Chu, Z. Y. & Wang, D. D. The extract of compound Radix Scutellariae on mRNA replication and IFN expression of influenza virus in mice. *Zhong Yao Cai*. **30**(1), 63–65 (2007).
42. Chu, M. *et al.* Evaluation of the Nano-TiO<sub>2</sub> as a novel deswelling material. *Molecules* **21**(1), 57–66 (2016).
43. Kim, E. S. *et al.* Chamaecyparis obtuse essential oil inhibits methicillin-resistant *Staphylococcus aureus* biofilm formation and expression of virulence factors. *J. Med. Food* **18**(7), 810–817 (2015).
44. Freeman, D. J., Falkner, F. R. & Keane, C. T. New method for detecting slime production by coagulase negative staphylococci. *J. Clin. Pathol.* **42**(8), 872–874 (1989).
45. Hess, B., Kutzner, C., van der Spoel, D. & Lindahl, E. GROMACS 4: Algorithms for Highly Efficient, load-Balanced, and Scalable Molecular Simulation. *J. Chem. Theory. Comput.* **4**(3), 435–447 (2008).
46. Oostenbrink, C., Villa, A., Mark, A. E. & van Gunsteren, W. F. A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. *J. Comput. Chem.* **25**(13), 1656–1676 (2004).
47. Schüttelkopf, A. W. & van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. *Acta. Cryst.* **D60**, 1355–1363 (2004).
48. Peschel, A. & Otto, M. Phenol-soluble modulins and staphylococcal infection. *Nat. Rev. Microbiol.* **11**(10), 667–673 (2013).
49. Chu, M. *et al.* Evaluation of human epidermal growth factor receptor 2 in breast cancer with a novel specific aptamer. *Cell. Mol. Immunol.* doi: 10.1038 (2015).

## Acknowledgements

This work was supported by Leading Academic Discipline Project of Beijing Education Bureau (BMU20110254), Natural Science Foundation of Liaoning Province (2015020694), Fostering Talents in Basic Science of the National Natural Science Foundation of China (J1030831/J0108), Beijing Municipal Natural Science Foundation (7162099) and Shenzhen Science and Technology Project.



## Author Contributions

M.C., Z.-y.C., and Y.-d.W. conceived the experiments, M.C., M.-b.Z., Y.-c.L. and J.-r.K. conducted the experiments, K.-l.Y., L.-y.D. and R.D. analyzed the results. R.-x.X., Y.-n.Y. and X.-y.L. prepared the figures. M.C. wrote the main manuscript text. All authors reviewed the manuscript.

## Additional Information

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Chu, M. *et al.* Role of Berberine in the Treatment of Methicillin-Resistant *Staphylococcus aureus* Infections. *Sci. Rep.* **6**, 24748; doi: 10.1038/srep24748 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>